Cadence Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Cadence Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-307,294	Closed	-$1.88M	–	475
2018 Q4	$1.88M	Buy	+307,294	New	+$1.88M	0.19%	165
2017 Q4	–	Sell	-173,808	Closed	-$1.06M	–	683
2017 Q3	$1.06M	Buy	173,808 +8,449	+5%	+$53.5K	0.07%	374
2017 Q2	$1.2M	Buy	165,359 +33,433	+25%	+$206K	0.08%	312
2017 Q1	$699K	Buy	131,926 +23,506	+22%	+$159K	0.05%	438
2016 Q4	$778K	Buy	108,420 +2,745	+3%	+$22.2K	0.05%	407
2016 Q3	$989K	Buy	+105,675	New	+$878K	0.07%	315

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Cadence Capital Management's PETX Position: Q1 2019 in Review

Cadence Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 307,294 shares — an estimated $1.88M sold.

Cadence Capital Management first reported a position in PETX in Q3 2016 and held it in 6 quarters. The position peaked at $1.88M in Q4 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

Cadence Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Cadence Capital Management sold 307,294 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $1.88M.
Cadence Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 6 quarters.
Cadence Capital Management's Aratana Therapeutics, Inc. position peaked at $1.88M in Q4 2018.
104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Cadence Capital Management's 13F filing for Q1 2019, filed 7 May 2019.